Abstract 2601

A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Naval Daver¹, Harry P. Erba², Nikolaos Papadantonakis³, Daniel J. DeAngelo⁴, Eunice S. Wang⁵, Marina Konopleva¹, Callum M. Sloss⁶, Jiuzhou Wang⁶, Kara E. Malcolm⁶, Patrick A. Zweidler-McKay⁶, and Hagop Kantarjian¹ ¹MD Anderson Cancer Center, Houston, TX; ²Duke Cancer Center, Birmingham, AL; ⁴Dana-Farber Cancer Institute, Boston, MA; ⁵Roswell Park Comprehensive Cancer Center, Buffalo, NY; ⁶ImmunoGen, Inc., Waltham, MA

BACKGROUND


CD123, the alpha-subunit of interleukin-3 receptor (IL3RA), expression is elevated on Acute Myeloid Leukemia (AML) blasts and leukemic stem cells compared with normal hematopoietic stem and progenitor cells.¹

CD123 is rapidly internalized making it well suited for antibody-drug conjugate (ADC)-based therapeutic strategies.

IMGN632 is a CD123-targeting ADC, comprising a high affinity anti-CD123 antibody coupled to a DNA alkylating payload of the novel IGN (indolinobenzodiazepine pseudodimer) class.

Previously published data ASH 2018: (n=33) demonstrated clinical activity across multiple dose levels (0.015-0.45 mg/kg) with complete remission(CR)/complete remission without complete hematological recovery (CRi) in 26% of R/R AML and responses in 2 of 3 relapsed BPDCN patients. DLTs seen only at higher dose levels \geq 0.18, 2 reversible veno-occlusive disease (VOD) and 1 prolonged neutropenia. Expansion cohorts enrolling at 0.045 and 0.09 mg/kg.⁴ Updates on Monday, December 9th at 3PM (Oral Abstract #734).

Pre-clinical data indicate IMGN632 combinations with azacitidine (AZA), venetoclax (VEN), and AZA with VEN result in increased survival in mouse models of AML (Abstract #1375).²



IMGN632: A Novel CD123-Targeting ADC³

Novel Anti-CD123 Antibody

- High affinity binding to CD123
- Unique epitope in extracellular domain

Novel IGN Payload (DGN549)

- DNA-alkylating activity, single strand DNA breaks (vs. double strand) Uniform drug-antibody ratio (DAR=2)

Novel Peptide Linker

Confers stability in circulation, and efficient intracellular payload release

Schema Safety Run-In IMGN632 dose levels (0.015, 0.045, 0.09)A: IMGN632 + AZA 3+3 AZA x7d, IMGN632 x1 on day 7 of 28 days B: IMGN632 + VEN 3+3 VEN x21d, IMGN632 x1 on day 7 of 21 days C: IMGN632 + AZA + VEN3+3 AZA x7d, VEN x28d, IMGN632 x1 on day 7 of 28 days D: IMGN632 monotherapy 0.045 mg/kg every 21 days Program Updates Continued phase I trial of IMGN632 as a single agent, currently enrolling three expansion cohorts: Untreated or R/R BPDCN, AML and B- or T-ALL, will be presented Sunday, December 8th from 6-8PM (Abstract #1334) Clinical safety and efficacy updates to the Phase 1 trial will be presented on Monday, December 9th at 3PM (Oral Abstract #734) Eligibility Registration This study is registered at clinicaltrials.gov NCT04086264. For more information please contact medicalaffairs@immunogen.com. REFERENCES ¹Ehninger A, Kramer M, Röllig C et al. *Blood Cancer J* 4:e218, 2014 ²Kuruvilla VM, McCarthy R, Zhang Q et al. ASH 2019, Abstract #1375 ³Kovtun Y, Jones G, Adams S et al. *Blood Adv* 2:848-858, 2018 ⁴Daver NG et al. Blood. 2018;132: Abstract 27.

- and efficacy of IMGN632 when administered in monotherapy for patients in (R/R) or treatment-naïve AML
- 3+3 escalation, with ability to expand multiple dose-levels
- IMGN632 administered in 4 distinct regimens:
- IMGN632 + azacitidine
- IMGN632 + venetoclax
- doublets)
- IMGN632 monotherapy as maintenance
- IMGN632 monotherapy at 0.045 mg/kg for MRD+ patients in remission after induction/consolidation
- IMGN632 dosing levels for combinations: 0.015, 0.045 and 0.09 mg/kg/dose

Study Design The IMGN632-0802 study is a multi-center Phase 1b/2 study to assess the safety remission with minimal residual disease (MRD+) after induction or consolidation or in combination in adult patients with CD123-positive, relapsed/refractory IMGN632 + azacitdine + venetoclax (enrollment follows safety assessment of Patients who benefitted from combination regimens may continue to receive Trial Endpoints Evaluate safety and tolerability and Recommended Phase 2 Dose (RP2D) when IMGN632 is administered with AZA, VEN, or with AZA and VEN in patients with Assess preliminary antileukemia activity when IMGN632 is administered in combination with AZA, VEN, or with AZA and VEN in patients with relapsed Assess MRD conversion rate using central flow cytometry-based testing Patients with prior bone marrow transplant are eligible (greater than 120 days)

Primary

- Combination cohorts
- R/R AML
- AML or untreated AML
- MRD+ cohort: IMGN632 monotherapy
 - Relapse-free survival (RFS)


Key Inclusion

- CD123+ AML
- Relapsed/refractory AML (up to 2 prior lines) or treatment-naïve
- Washout period 14 days (except for checkpoint inhibitors 28 days)
- MRD+ AML confirmed by central lab

Key Exclusion

Patients with history of veno-occlusive disease

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ASH and the author.



This trial is open and enrolling; ~35 centers in US and Europe plan to participate

